RA Capital Nexus Fund III, L.P.
SEC CIK 1883840 · EDGAR
BoughtSold
Most active insiders at SION, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Thompson Peter A. | Dir | — | $55.67M |
| 2 | ORBIMED ADVISORS LLC | Dir | — | $52.73M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | — | $27.34M |
| 4 | Booth Bruce | Dir | — | $22.09M |
| 5 | RA Capital Nexus Fund III, L.P. | Dir | — | $14.76M |
| 6 | WINKELRIED JON | 10% | — | $10.00M |
| 7 | Cloonan Michael | Pres, CEO, Dir | — | $5.13M |
| 8 | OrbiMed Capital GP VIII LLC | Dir | — | $2.95M |
| 9 | Fitzpatrick Jennifer | CLO, Head of Program Mgmt | — | $1.21M |
| 10 | Kolchinsky Peter | Dir, 10% | — | $1.20M |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-10-28 | 2025-10-24+ | SION | Sionna Therapeutics, Inc. | RA Capital Nexus Fund III, L.P. | Dir | S - Sale | $39.51 | -373.6K | 6.91M | -5% | -$14.76M |
| I | 2025-03-17 | 2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | RA Capital Nexus Fund III, L.P. | Dir | P - Purchase | $13.50 | +1.30M | 4.28M | +43% | +$17.50M |
| DMI | 2024-09-18 | 2024-09-16 | BCAX | Bicara Therapeutics Inc. | RA Capital Nexus Fund III, L.P. | Dir | C - Cnv Deriv | — | +5.12M | 2.62M | New | — |
| DMI | 2024-09-18 | 2024-09-16 | BCAX | Bicara Therapeutics Inc. | RA Capital Nexus Fund III, L.P. | Dir | P - Purchase | $18.00 | +1.83M | 2.65M | +224% | +$32.99M |
| DMI | 2023-02-16 | 2023-02-14 | MLYS | Mineralys Therapeutics, Inc. | RA Capital Nexus Fund III, L.P. | Dir | P - Purchase | $16.00 | +1.25M | 1.31M | +2,041% | +$20.00M |
| DMI | 2023-02-16 | 2023-02-14 | MLYS | Mineralys Therapeutics, Inc. | RA Capital Nexus Fund III, L.P. | Dir | C - Cnv Deriv | — | +1.93M | 192.8K | New | — |
Purchase Sale Sale after option exercise All abbreviations